<SEC-DOCUMENT>0001214659-18-003284.txt : 20180503
<SEC-HEADER>0001214659-18-003284.hdr.sgml : 20180503
<ACCEPTANCE-DATETIME>20180503105403
ACCESSION NUMBER:		0001214659-18-003284
CONFORMED SUBMISSION TYPE:	PX14A6G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20180503
DATE AS OF CHANGE:		20180503
EFFECTIVENESS DATE:		20180503

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PX14A6G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		18802318

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mercy Investment Services, Inc.
		CENTRAL INDEX KEY:			0001699865
		IRS NUMBER:				263224636
		STATE OF INCORPORATION:			MO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		PX14A6G

	BUSINESS ADDRESS:	
		STREET 1:		2039 NORTH GEYER ROAD
		CITY:			ST. LOUIS
		STATE:			MO
		ZIP:			63131
		BUSINESS PHONE:		314-909-4609

	MAIL ADDRESS:	
		STREET 1:		2039 NORTH GEYER ROAD
		CITY:			ST. LOUIS
		STATE:			MO
		ZIP:			63131
</SEC-HEADER>
<DOCUMENT>
<TYPE>PX14A6G
<SEQUENCE>1
<FILENAME>d53180px14a6g.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Securex Filings LLC
    Document created using EDGARfilings PROfile 4.3.3.3
    Copyright 1995 - 2018 Broadridge-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div style="TEXT-ALIGN: center"><img src="mis_logo.jpg"><br>
<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">PROXY MEMORANDUM</div>

<div><br>
</div>

<div>
<table id="z711e610816c6435e8e9daebe89a36536" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="VERTICAL-ALIGN: top; WIDTH: 63pt; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">To:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto; align: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Biogen Inc. Company Shareholders</div>
</td>
</tr>
</table>
</div>

<div>
<table id="zff97819298ed47dfa927f70c3f001374" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="VERTICAL-ALIGN: top; WIDTH: 63pt; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Subject:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto; align: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Shareholder resolution on extent to which risks related to public concern over drug pricing are integrated into incentive compensation policies for senior executives</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z9883ae12f7fc4ae88d89861712f105c1" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="VERTICAL-ALIGN: top; WIDTH: 63pt; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Date:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto; align: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">May 3, 2018</div>
</td>
</tr>
</table>
</div>

<div>
<table id="zcb0b3d8fbac94364a0de354dff46aabb" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="VERTICAL-ALIGN: top; WIDTH: 63pt; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Contact:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto; align: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Joshua Brockwell, Investment Communications Director, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>joshua@azzad.net</u></font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 63pt">Donna Meyer, Director of Shareholder Advocacy, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>dmeyer@mercyinvestments.org</u></font></div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: left">
<hr style="BORDER-TOP: medium none; HEIGHT: 1pt; BORDER-RIGHT: medium none; BORDER-BOTTOM: medium none; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; WIDTH: 100%; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="center" noshade="noshade">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">At the upcoming Biogen Inc. (&#8220;Biogen&#8221; or the &#8220;Company&#8221;) annual shareholders&#8217; meeting on June 12, 2018, shareholders will have the opportunity to vote on a Proposal (the &#8220;Proposal&#8221;) sponsored by multiple shareholders<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-WEIGHT: bold">1</sup> to disclose how Biogen considers risks stemming from public concern over high drug prices in setting incentive pay arrangements for senior executives. <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">We urge you to vote FOR proposal #5 as described below.</font></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">RESOLVED, that shareholders of</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Biogen Inc. Company (&#8220;BIIB&#8221;) urge the Compensation Committee (the &#8220;Committee&#8221;) to report annually to shareholders on the extent to which risks related to public concern over drug pricing strategies are integrated into Biogen&#8217;s incentive compensation policies, plans and programs (together, &#8220;arrangements&#8221;) for senior executives. The report should include, but need not be limited to, discussion of whether incentive compensation arrangements reward, or not penalize, senior executives for (i) adopting pricing strategies, or making and honoring commitments about pricing, that incorporate public concern regarding the level or rate of increase in prescription drug prices; and (ii) considering risks related to drug pricing when allocating capital.</font></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #212121">The core request of the Proposal is for the Board to explain whether and how Biogen&#8217;s incentive compensation arrangements, individually and together, incorporate public concern about high drug prices.&#160; The Proposal asks how incentive compensation arrangements encourage senior executives to behave consistent with the Company&#8217;s professed goal of &#8220;evaluating the impact a therapy has on the</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #578196; BACKGROUND-COLOR: #ffffff">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #212121">entirety of the health care system, including the financial implications on payers and patients</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #578196; BACKGROUND-COLOR: #ffffff">.&#8221;</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;COLOR: #212121">2</sup></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">We believe that incentive compensation programs should not just encourage executives to achieve financial objectives, but also to manage key business risks effectively. In its 2018 proxy statement, Biogen states both its annual bonus and long-term incentive plans are designed to support long-term value creation<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">.</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller"><font style="BACKGROUND-COLOR: #ffffff">3</font></sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">&#160;</font>But the company performance metrics used in those plans emphasize revenue, which is used for both the annual bonus and the cash-settled performance unit (&#8220;CSPU&#8221;) component of the long-term plan, and earnings per share, which is used in the annual bonus formula.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">4</sup></div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></font><br>
<br>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">1</sup> Mercy Investment Services, Inc.; Azzad Asset Management, Trinity Health; UAW Retiree Medical Benefits Trust; The Sisters of St. Francis Charitable Trust; Boston Common Asset Management, LLC; Northwest Women Religious Investment Trust; Oblate International Pastoral Investment Trust; Domini Impact Investment, Inc.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">2</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #212121">//www.biogen.com/en_us/about-biogen/positions-pricing.html#pricing-principles</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller"><font style="BACKGROUND-COLOR: #ffffff">3</font></sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">&#160;</font>2018 Biogen Proxy Statement,<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #ff0000">&#160;</font>p. 37.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">4</sup> 2018 Biogen Proxy Statement, pp. 42, 47.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Reactions of the public, health care payers, policymakers and prescribers to high drug prices pose a serious challenge, in our view, to sustainable value creation by pharmaceutical companies. High drug prices may create several kinds of risk:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="zdb8630531e694a4098ea4c7085f590c5" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">&#167;</td>
<td style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">They may damage corporate reputation, as illustrated by Mylan&#8217;s 2016 EpiPen controversy. According to Gallup, the pharmaceutical industry&#8217;s favorability rating stands at 33 percent, lower than the 23 other industries included in the poll.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">5</sup> Poor reputation can make it more difficult to recruit and retain talented employees.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">6</sup></div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff">
<table id="z9cd9f3582bfa45b580ff84cb8212b816" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">&#167;</td>
<td style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">In a <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Harvard Business Review</font> article ominously titled &#8220;The Cost of Drugs for Rare Diseases is Threatening the U.S. Healthcare System,&#8221; a neuromuscular disease specialist who treats SMA patients estimated that the cost of treating the most severely affected U.S. patients for just the first year would be $3.8 billion.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">7</sup> One analyst speculated that Spinraza&#8217;s pricing might be &#8220;the straw that breaks the camel&#8217;s back in terms of the U.S. market&#8217;s tolerance for rare disease drug pricing.&#8221;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">8</sup></div>
</td>
</tr>
</table>
</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="z777581cc782c4722bc6314857080b7a1" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">&#167;</td>
<td style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">High prices may spur regulatory intervention. Legislation has been passed in several states addressing pricing-related issues, including notice of intended price increases, and many more measures have been introduced and advanced through committee.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">8</sup></div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">Biogen has been the subject of significant criticism for its pricing of Spinraza, which treats spinal muscular atrophy (&#8220;SMA&#8221;), a deadly genetic muscle-wasting disease. The first-year price for Spinraza was set at $750,000 with each year thereafter costing $375,000.</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller"><font style="BACKGROUND-COLOR: #ffffff">9</font></sup><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">Controversy has also followed from Biogen&#8217;s price hikes for its drugs to treat multiple sclerosis (&#8220;MS&#8221;). Members of Congress launched an investigation into the price increases, requesting information from Biogen and other makers of MS drugs and</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; BACKGROUND-COLOR: #ffffff">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #212121; BACKGROUND-COLOR: #ffffff">citing concern that prices were rising in lockstep. Biogen&#8217;s stock price dropped after the investigation was announced</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">.</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller"><font style="BACKGROUND-COLOR: #ffffff">10</font></sup>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #212121">Some companies have responded to public concerns about prices by committing not to raise prices by more than a certain amount per year. For example, Sanofi committed to limiting price increases to the national health expenditure growth projection, which was 5.4 percent in 2017.</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;COLOR: #212121">11</sup><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;COLOR: #212121">&#160;</sup>We are concerned that Biogen&#8217;s incentive pay arrangements, which use revenue and earnings per share as metrics for the annual bonus (together with strategic goals) and revenue and free cash flow as the metrics for the CSPUs, may overlook the pricing pressure risks the company faces and not take into account these risks in compensation arrangements.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">12</sup></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #212121; TEXT-ALIGN: justify">In our view, rewarding executives for boosting revenue can create additional risks when that revenue is generated primarily or solely through price increases. In 2017, holders of approximately 80 percent of Mylan shares voted opposed management&#8217;s &#8220;say on pay&#8221; proposal,<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">13</sup> following a &#8220;vote no&#8221; campaign by institutional investors that cited high pay &#8220;amid a public and regulatory backlash&#8221; related to EpiPen pricing.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">14</sup></div>

<div>&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">5</sup>&#160; news.gallup.com/poll/12748/business-industry-sector-ratings.aspx</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">6</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160; </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>See</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> http://www.mandrake.ca/bill/images/corporate_responsibility_white_paper.pdf (summarizing evidence that perceptions regarding corporate social responsibility drive higher levels of employee engagement and retention); </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>see</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>also</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>https://business.missouri.edu/sites/default/files/publication/turban_greening_1997_amj.pdf</u></font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: 'Times New Roman', serif">7</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>https://hbr.org/2017/04/the-cost-of-drugs-for-rare-diseases-is-threatening-the-u-s-health-care-system</u></font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: 'Times New Roman', serif">8</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>https://www.bizjournals.com/boston/news/2017/01/03/biogen-boosts-price-of-top-drugs-analyst-says.html</u></font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: 'Times New Roman', serif">9</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font>https://www.npr.org/sections/health-shots/2017/08/01/540100976/drug-puts-a-750-000-price-tag-on-life</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: 'Times New Roman', serif">10</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font>https://www.investors.com/news/technology/biogen-teva-slip-after-democrats-launch-ms-drug-pricing-probe/</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: 'Times New Roman', serif">11</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>http://mediaroom.sanofi.com/sanofi-pricing-principles-for-the-u-s/</u></font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: 'Times New Roman', serif">12</sup><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-FAMILY: Calibri, sans-serif">&#160;</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2018 Biogen Proxy statement, pp. 42, 47.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">13</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>See</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><a style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" href="http://www.sec.gov/Archives/edgar/data/1623613/000119312517216777/d412323d8k.htm">www.sec.gov/Archives/edgar/data/1623613/000119312517216777/d412323d8k.htm</a></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">14</sup> www.sec.gov/Archives/edgar/data/1517047/000121465917003708/d530170px14a6g.htm</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Biogen unsuccessfully argued to the SEC Staff that it should be allowed to exclude the Proposal because the Company had substantially implemented the Proposal through its regular proxy statement disclosure.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">15</sup> It repeats that argument in its Statement in Opposition to the Proposal. However, the Proposal asks for an analysis of the relationship between an aspect of the business climate and senior executive pay arrangements. Biogen&#8217;s existing disclosures do not mention drug pricing-related risks, but rather describe general compensation arrangements as required by SEC rules. Thus, Biogen has not satisfied the Proposal&#8217;s core objective.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">We believe that the information sought by the Proposal would give shareholders valuable insight about how Biogen&#8217;s executive pay practices balance financial goals and management of pricing-related risks. <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">We therefore urge shareholders to vote FOR proposal #5.</font></div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">15</sup>&#160;<a style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" href="http://www.sec.gov/Archives/edgar/data/1517047/000121465917003708/d530170px14a6g.htm">www.sec.gov/Archives/edgar/data/1517047/000121465917003708/d530170px14a6g.htm</a></div>

<div>&#160;</div>

<div>&#160;</div>

<div><br>
<hr style="BORDER-TOP: medium none; HEIGHT: 2px; BORDER-RIGHT: medium none; BORDER-BOTTOM: medium none; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="center" noshade="noshade">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>mis_logo.jpg
<TEXT>
begin 644 mis_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!H17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    1    3@
M      !@     0   &     !<&%I;G0N;F5T(#0N,"XR,0  _]L 0P ! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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MD'[8G_AO_@K_ /1!4YO^#H__ ()_J<?\*A_;#/NO@#X*D?\ K076OX)-\/\
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M;_X*_P#T05'_ !%(?\$__P#HD'[8G_AO_@K_ /1!5_!715?\2W>&7_0+G/\
MX=ZO_P K_J_I8_XCYXA?]!.5?^&NE_\ )G^NO\&?BEX?^.7P?^%/QK\)V>LZ
M=X5^,'PV\"_%+PSI_B*WLK3Q!8^'_B!X7TOQ9HUGKMKINH:OIUMK-MIVKVT.
MIV^GZKJ=E#>I/':ZA>P+'<R%>"?\$[_^4?\ ^PS_ -F=_LR_^J5\$T5_ 6;X
M:E@\VS/!T%)4<+F.-PU%2?-)4J&)JTJ:E+[4N2*N^KU/[9RO$5,7EF78JLTZ
MN)P.$Q%5Q7+%U*V'IU)M16B3E)V71:'QW_P7V_Y1*_M8?]T)_P#6EO@W7^;/
M7^DQ_P %]O\ E$K^UA_W0G_UI;X-U_FSU_<GT6_^3?YQ_P!ECF'_ *I.'C^.
M_I&_\EOE?_9*X'_U;YX%%%%?TE*_+*V]G;UL?@(5_I/_ /!&GX=_#_5_^"9?
M[)&I:MX%\':IJ%W\/]9>[O\ 4?#&B7MY=./''B6,/<W5S8RSS,(XXT#2R,0D
M:+G:J@?YL%?Z%'_!'K]N+]CWPG_P3\_9@^%GBK]I;X,^&?B+X5\%:MIOB/P;
MX@\>:%HVOZ-?S^-/$=Q#:7]CJ-W;20S2P7$$T:G(:.5#GG _F/Z3>&S"MP9D
MZP=#%U9QXAI2FL-"K4E&'U#&IRG[)-QA=I<TK1NTKW:3_?/H]U\'1XJS5XVK
MAJ,)Y)*,'BJE*G&4UC\%+EC[5I2GRJ3Y5>5DW:US]L#\)_A8RM_Q;?P ".F/
M!WAWD[6&#_Q+NG.>>,@&OY$O^"TW[/VA^(/^"PG_  3F\+:#X9T_3M"^+,7P
M5\+:KIVC:18V&GW=KH7Q^UVZ\0R/;VMO%:3/;Z'JD<]S]HC=9(TMUDW*J"OZ
MU=&^.7P9\061OM ^*WPZURR.#]KTCQKX:U"W"E22YFMM3DC"HJLSY;(49 .1
MG^>+X\?'#X(?M=?\%V?^"?'@/X4>(] ^(EM^SUX,^+_B'QWXG\.WEMJFC6/B
MV+PUXG\3Z3X9BU.VFFM+S4O#D_AC3+^^%J7CL9]<AMO/DN4NHK3^:/#&OFF6
MYYG>92CBX4\NX.XJJ59U?;1I4FLLC5I\[FXQA+VV'IQ2<HR;J67Q,_H;Q$I9
M3F&593A*57!2JX_B3(%0IT94I5*].&-C[90C34I."IR;GIRM)I^7[7?M1_ ;
MX5>-/V9_VB/!UEX \#VUYX@^!OQ5T*!].\*^'+;4K&XUGX?:_I]K<V4D=@DU
MG?02W*2V<R%)89UBEC96537XN?\ !LS\)_ VJ_L(?$+QEK_A'PWX@U'Q+^T=
MXK@BO]:\/:3J3_V;H?PY^%EK##93WUG/*MG%J=QK(1$D^SES))$H+R,WN/[)
MGBSQEXO_ ."KG_!8SP%X@\6^)]7\(:7X.^ ECH7A?4M?U34?#^AV]_\ #0Q/
M_8ND7EP]AI7VI;^[DN?[/M;3+R*LQN^7KYH_X-K_ -JWX%Z9^RKJO[+^O^.-
M!\+?&GPW\5/&_BAO"&N3G1K[Q%H7B&+0W@U72'OQ#8ZC+IU];7N@7>GV%S+?
MVBZ;9S7%HMO>6D\_J0R[-<KX"X[R>A7Q&8SAF/ASG%1X)U:JHX3.LHS3,JU6
MK+WI2ITIRP=&I:5HU)IZJ[7D+&Y-C.,^$,UJT\/@85<'QIE-.GBE1HQJ8K+<
M?EV&IJ$)6C[5PIU90:?P<R5D[']*J?"CX5XY^&OP_P"O?P;X<_\ E;7\@O\
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MAYIP?G4:L<2W%4(K$U)Q4)RJ?#)\L8WO>-F?F/\ LK_\%@/V-/AM_P %'_\
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MV=];J[;UWU?4_E:HK3FM-)-:-M:.V[U?^844459!_JN?\$[_ /E'_P#L,_\
M9G?[,O\ ZI7P311_P3O_ .4?_P"PS_V9W^S+_P"J5\$T5_D?Q#_R/\\_['&9
M_P#J;7/].\B_Y$F3?]BK+_\ U$HGQW_P7V_Y1*_M8?\ ="?_ %I;X-U_FSU_
MI,?\%]O^42O[6'_="?\ UI;X-U_FSU_;OT6_^3?YQ_V6.8?^J3AX_D+Z1O\
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M2ZQTE).S2:>NRLW]A93_ ,/I?^"PPRJ :5^S/D_,0H'@"Q'J.!R>"OX=H/\
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M_J#_ !=^$?PA^$?A#]L+]HSPWX*L=!^)GQ(^#_B'5_BCXTLI+UM4\6V_PO\
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MCZ@]H91<1V,4'Q4N)I;F)EN4F\A9)%DE5(OM&V''S1\6_P!@/]M7X%VMW?\
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MS(9)(I-CC?%(\;91F!_S^#\0_B".3XY\9 <\GQ-K8^ZI8_\ +[V568^B@D\
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M?NFY?'7C!XW$GS#Q/K3(RQ /+R+XJ1& &DZA  S8'-.?XA?$%<;_ !QXR7S
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MCSPS\6_A]\9?VE?C]XMUSX8?LO\ P$C@'B;Q!X:L+.\\4_$SQKJ4HDT/X4>
M#?BY@L_$.JK<:?;77B'4=)GTG2FUG1W,_P!G&HSZ=@']JOX)>'W.G> _V#OV
M:(?"L:K#%%\4=0^./Q7\:SP1($675O&LGQ=\)0RWMRY<27NC^&]"_LZ!\Q07
MKQD2?=>K^'-4\2_\$ O!UQX$M[B^7PA^VEJGB/XOQ:);&26VL(-/\5Z;I^I:
M[:6(5H[6TM=4\%)--?1O;1V<>G7"+%-%'<I^&^ IP<$>^<,/[K 'H>_(/O0I
M6V2^:C)[+HT[:ZKK9ZG[7PA27B%G?'F8\08_-:^&R3BW,N$\JX:RW.<?E6$R
M/"9!*G@WCZZRC&8:KCL9GE2-;'^TQDYPHTI4881<G/4J?7_[06N_LP>)/!'P
M!^(OP?\ A(GPO\:^)KWQO-\;_A9I/Q,\1^+?!5O'X6\3:3;>&6\.77B2;4_'
MWAFV\:Z>-7U&^B?Q.1;)/;C2O+ELDNJ^[_&'[-O[+/[6O[ .J?M+_L@?"N7X
M1?'O]FN_GE_:(^!^D>//%?CNWU;P!+<7%W)X]@O?&FI3:G<V=A9)!XAAOK=+
M:5K/3/&F@W"WEQ90WMW^)2P(#E5&XJB%PL:.Z1 B,,410=BG"DCIGN3G[R_X
M)P_M%:]^SE^U5\/KVUTA/%/@KXMW,/P.^*?@Z]GF32O%G@7XCZE8>&;RTU&R
M21(+^;PU+K;>)-'-Q%-FX:_TYUEM=0N+=B]][6;N[)+[M-+];:=;.R1T<;\'
MY[DO". S7A#B7B'%9SP!F&;<4X:AF6>9A5I\1954QN(S#,.$,[^N5:E/-,-/
M+\1_9V68C$UYU\MAAZ'LIQIQLN4_9"^$GP[\7>(_%_Q;^/\ 9ZHW[-GP#\/2
M>+OB@+275=+/C#Q)<B2Q^''P:L-3TR6TU.W\0?$7Q@L.G1MI<L;6NCZ;K&IS
MWEI8_9+NY^4M?U&PU;7-7U/2O#VG>%-,O]0NKJP\-Z3>:GJ.GZ+:2R%H=.M=
M1UF\O]4U&&T3$"7][=/+=J@G"01ND$?Z?_\ !3/1-._91^(6I_\ !/CX2:CJ
M\?P=^&/B%_BGXENM3EM(_$7Q&^(_Q(TNSU[1;_Q7=:+;V&G7FG?"WP+?:%X&
M\#6,$4+03V?B;7=2@O)]6TPZ-^56W: ,D\=2,<#A0% "JJ(%C1455"(O&<DZ
M4VE:7174G;7F?16;T7KJ[OL>]X>YCB^+*#\0ZU2MALLXMRS!3X6R*=95%EO#
MN'M5HX^O"#:6/S[%XK$8ZISJ-2A@J>"P;YO8-G^FO^P3_P F,?L7_P#9IW[.
MG_JG_!U%'[!/_)C'[%__ &:=^SI_ZI_P=17AR^*7^)_F?X+<9_\ )8<6?]E+
MGO\ ZM,4?)__  7%_P"47/[3^>G_ !97U_Z.'^$OI7\&7P8TSP)J/CO1[GXB
M?$:T^&GAW0;[2]=GUF[\+>*/%[:@-/UK3'N=*L](\*V=U>MJ$M@UW<V<ERUM
M8F6U%O=3"*X85_>9_P %Q?\ E%Q^T_\ ]T5_]:'^$M?P8_!OX+^//CWXTM_A
MY\-+;0M2\8:A;3SZ3HVM>+?"_A!]7-J5EN+73+OQ7J^CV-Y?168N+T6<-PUP
M\%K,1'_%7=A/@>E_?>FO\L>VI_I[]"&OAL/X"<;U<?F-3*LNAQ]Q)/'XVE7I
MX:>&PL.#^$'B,1"K6IU:4:E'#.NXNI3E!<S<HM)6^MOC[\>/!WA7]N#4/VQO
MV;/BO)XMN=9_:!\1?&[1;3_A$?%O@SQ#X1BO_%%KKT_ACQ)'XCL1IVK0^(=*
MOM7\,:G>:)J5^D]G<74D\7E'[,NY_P %"/VJ_"?[:W[5KZAX=\20_#;]G/0F
MO[7X;-?>%]7DL/#%QXPMY?%GQ+\9:IX8T#3KO7;S7O''Q(U35[C5Q%:W,TT4
M%A(]TME+<31_*_@C]F+XQ?$S0/C#XE^'VA:-XQTSX$6-[K'Q&70/&'A;4]1T
M_P /V"1R7/B+1=)M-7FU#Q5H@#2I%?\ ANWU..1[.[8A8(?/;@?#WPO\4>*/
M!'C?XA:5/X7_ .$7^'LNEP>)+B_\9>&=-U))=<CU)M$BTWP]>:G%XAU=]4GT
MJ]M;9-.TNX831^9*L=LD]Q#U>\K:-)ZK=<R3U=^JNODT[6U/Z;RSA'@#!YID
M.;K-\-B^).!N'Z/!U/,JF.PN(QE&GQ-AL%3R&GC8>Q6%JX^>&C%9/[?#/G^O
M8FC&/^V5.;]1_P#@H=\>?V4?VA_@M^R5X=^$'QBU*^\3_LL? JQ^$6I:+XE^
M&'C_ $/_ (3V>QT?P7I$6J>'=6:.>PM%\[P_J-P+7Q'%8@Q75O+-<ET98\;_
M ()'_M#?LY?LD?%_Q=\<OCK\3;[P_+J/PZ\8?#?1_!6@?#GQ9XLUQIO$MWX3
MN4UVYU/3(8]!M=.@CTZ[A-M%<O>NQE4K$HWM\ _$?]G;XG_"CPM\+?&OC6P\
M.:?X7^,^C-X@^&VK6GCCP?JZ^(='AOH]-N]0-OI6MW=QI5OIM[+';:D^KQV7
M]GS)=1W*H]G<!>HT']D7XV^)_C)=? '1=-\'W7Q4MM#A\0)X??XE_#^UL[ZR
MN-%C\1QV^G>(;SQ)!X?N]6CT:1=0O-*_M*.\M+<.TL>8W"CO_+;1+5/JM-[W
MO':][K74\V'"/ &&\-<=P/5XQ=/@S-O]9J^+QU;,LGJ8JC@*7$$\7Q13PN,K
MX*,*:I9O7Q$<;[*,'A:U3ZO'D@[+T0? 7]B%YUC7_@H#K4.G!MH>;]D#XGS:
MA%"P1BR[?'$<4UY'(IECF8R+)-&DTJ22MO7EOVGM:_9[^)'[47B*7X(:C;_#
M_P#9\GB\%^&_"VNZGX2UJU.G:;X?^'/AG0-4\0ZEX6TBQU/Q#+<:GXET;6M5
MG"O=:A>S:D)KYD:97;SWQY^SM\1_A]HNA:_J,O@+Q-I_B3Q&_A+2S\./B?X
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MIX/*,/EDZ<9K$5G6A5>7TJTI1HX9/GI.49^ZW_IL?L$_\F,?L7_]FG?LZ?\
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MCXS\<^*?%7Q":\D\;ZYJTU[XGFU&P&FZA-JA2.*22\M!;VJI<&**%7VPK]T
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MXOW'AWP#\))3I?B_S[;4+ZP^(NK2V-A#H.B+:37UR/D%OVPO@""0G_!/;X'
M$EL#XY_M92X+_.P:7_A<^7<,Q#MSE@>6/S'X>\2^*?$GC+6K_P 2>+->UCQ/
MXAU643ZIKWB/5=2U_6]3N/+CB:XU#6-9N[_5+Z=XXD4O=7DPCP! D**$&"
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>%P]'#4Y5&G.4*%.-*#FXQC%S<8IR<8Q3=[12T/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
